RECRUITING Not applicable ClinicalTrials.gov

NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study

Sponsor: University of Texas Southwestern Medical Center • ClinicalTrials.gov ID: NCT06593327

Registry updated: 2026-09-29

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.

Interventions

Intensive Prevention Strategy (Behavioral)
Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.

Eligibility criteria

Inclusion Criteria: * Primary Care Provider that sees diabetes patients in clinic Exclusion Criteria: * Provider does not see patients with Diabetes

Conditions

Type 2 Diabetes Diabetic Cardiomyopathy Heart Failure Cardiometabolic Diseases

Locations

University of Texas Southwestern Medical Center — Dallas, Texas, United States
Parkland Health & Hospital System (PHHS) — Dallas, Texas, United States
Baylor Scott and White - Health System — Dallas, Texas, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment